2,853 Shares in Hologic, Inc. (NASDAQ:HOLX) Purchased by Trust Asset Management LLC

Trust Asset Management LLC purchased a new position in shares of Hologic, Inc. (NASDAQ:HOLX) during the fourth quarter, Holdings Channel reports. The firm purchased 2,853 shares of the medical equipment provider’s stock, valued at approximately $204,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Stevens Capital Management LP acquired a new position in Hologic during the fourth quarter worth about $806,000. Meritage Portfolio Management boosted its position in Hologic by 6.6% during the fourth quarter. Meritage Portfolio Management now owns 141,485 shares of the medical equipment provider’s stock worth $10,109,000 after acquiring an additional 8,806 shares during the last quarter. Corbyn Investment Management Inc. MD acquired a new position in Hologic during the fourth quarter worth about $247,000. GAMMA Investing LLC acquired a new position in Hologic during the fourth quarter worth about $155,000. Finally, California Public Employees Retirement System boosted its position in Hologic by 2.0% during the fourth quarter. California Public Employees Retirement System now owns 1,422,317 shares of the medical equipment provider’s stock worth $101,625,000 after acquiring an additional 27,461 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CFO Karleen Marie Oberton sold 14,940 shares of the company’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $75.00, for a total transaction of $1,120,500.00. Following the sale, the chief financial officer now directly owns 103,916 shares of the company’s stock, valued at approximately $7,793,700. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, Director Scott T. Garrett sold 16,441 shares of the company’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the sale, the director now directly owns 48,611 shares of the company’s stock, valued at approximately $3,670,130.50. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Karleen Marie Oberton sold 14,940 shares of the company’s stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $75.00, for a total transaction of $1,120,500.00. Following the sale, the chief financial officer now directly owns 103,916 shares in the company, valued at $7,793,700. The disclosure for this sale can be found here. Insiders have sold a total of 32,846 shares of company stock valued at $2,473,443 in the last ninety days. Company insiders own 1.75% of the company’s stock.

Hologic Trading Down 1.3 %

Shares of Hologic stock traded down $1.00 on Thursday, reaching $75.71. The company had a trading volume of 1,190,936 shares, compared to its average volume of 1,779,627. The firm’s 50 day moving average price is $75.98 and its two-hundred day moving average price is $72.74. The firm has a market cap of $17.77 billion, a PE ratio of 35.88, a PEG ratio of 2.61 and a beta of 1.00. Hologic, Inc. has a 52-week low of $64.02 and a 52-week high of $87.88. The company has a debt-to-equity ratio of 0.55, a quick ratio of 3.18 and a current ratio of 3.89.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.95 by $0.03. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $989.32 million. Hologic had a net margin of 12.98% and a return on equity of 18.91%. The business’s revenue was down 5.7% on a year-over-year basis. During the same period in the previous year, the firm earned $1.07 EPS. Sell-side analysts predict that Hologic, Inc. will post 4.01 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have weighed in on HOLX. Needham & Company LLC reiterated a “buy” rating and issued a $90.00 target price on shares of Hologic in a report on Wednesday, April 10th. Raymond James boosted their target price on shares of Hologic from $85.00 to $88.00 and gave the company an “outperform” rating in a report on Friday, February 2nd. Citigroup upgraded shares of Hologic from a “neutral” rating to a “buy” rating and boosted their target price for the company from $80.00 to $95.00 in a report on Wednesday, April 3rd. Evercore ISI boosted their target price on shares of Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a report on Thursday, April 4th. Finally, William Blair reiterated an “outperform” rating on shares of Hologic in a report on Friday, February 2nd. Six analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, Hologic presently has an average rating of “Hold” and an average price target of $87.00.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.